Details

Autor(en) / Beteiligte

• Sobti, R. C.,
• Krishan, Awtar,
• Sobti, Aastha,

Titel

Biomarkers in Cancer Detection and Monitoring of Therapeutics. Volume 1

Auflage

First edition

Ort / Verlag

Oxford, England : Stacy Masucci,

Erscheinungsjahr

[2024]

Link zum Volltext

• Elsevier Books AutoHoldings

Beschreibungen/Notizen

• Includes bibliographical references and index.
• Intro -- Biomarkers in cancer detection and monitoring of therapeutics: Volume 1: Discovery and Technologies -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Milestones in cancer research -- 1. Introduction -- 2. Landmark researches -- 2.1. Aberrant chromatin -- 2.2. Rous sarcoma virus -- 2.3. Cancer metastasis -- 2.4. Smoking: A cause of lung cancer -- 2.5. Chromosomal translocations in cancer -- 2.6. Suppressed apoptosis -- 2.7. Context dependence of carcinomas -- 2.8. Protein phosphorylation in cancer -- 2.9. The immune system in cancer -- 2.10. Circumventing the blocks: Cancer drug resistance -- 3. Summary -- References -- Chapter Two: Cancer burden: Epidemiology, racial, and geographical disparities -- 1. Introduction -- 2. Global burden of cancer -- 3. Social class disparities in cancer -- 4. Racial disparities in cancer -- 5. Risk factors for cancer -- 6. Reasons for disparities in cancer -- 6.1. Health system settings -- 6.2. Environmental settings -- 7. Response to the burden of cancer -- 8. Conclusion -- References -- Chapter Three: Technological evolution in cancer diagnosis and therapeutics -- 1. Introduction -- 2. Cancer diagnosis -- 2.1. Nanotechnology-mediated cancer diagnostics -- 2.2. Molecular techniques for cancer diagnostics -- 2.3. Advancement in biopsy -- 2.4. Radiomics and pathomics -- 2.5. Biomarker and biosensors -- 2.6. Other omics-based technologies -- 3. Cancer therapy -- 3.1. Nanotechnology-mediated cancer therapy -- 3.2. Immunotherapy -- 3.3. Gene therapy -- 3.4. Hormonal therapy -- 3.5. Molecular radiotherapy -- 3.6. Magnetic hyperthermia -- 3.7. Other techniques -- 4. Conclusion -- References -- Chapter Four: How does time speak about cancer, its diagnosis, treatments, and challenges? -- 1. Introduction -- 2. What causes cancer? -- 3. New knowledge about cause of cancer -- 3.1. Carcinogens.
• 3.2. Chemical carcinogens -- Tobacco -- Coal tar -- Benzene -- Hydrocarbons -- Arsenic -- Asbestos -- 3.3. Viruses -- Rous sarcoma virus (RSV) -- Epstein-Barr virus (EBV) -- Hepatitis B virus (HBV) -- Human T-lymphotropic virus-1 (HTLV-1) -- High-risk human papillomaviruses (HPV) 16 and HPV 18 (some other α-HPV types are carcinogenic) -- Hepatitis C virus (HCV) -- Kaposi's sarcoma herpesvirus (KSHV) -- Merkel cell polyomavirus (MCV) -- Some key discoveries and events in tumorigenic virus research -- 3.4. Environmental radiations -- Ultraviolet (UV) radiation -- 3.5. Medical radiations -- 3.6. Medication causes -- 3.7. Life style factors -- 3.8. Mutagens -- 4. Animal models and chemical carcinogenesis -- 5. History of cancer treatment -- 5.1. Chemotherapy -- 5.2. Surgery -- 5.3. Radiation -- 5.4. Immunotherapy -- 5.5. Therapy using nanotechnology -- 5.6. Treatment beyond the limit -- 6. Major breakthroughs in cancer research -- 7. Cancer in India since antiquity -- 8. Conclusion -- Acknowledgment -- References -- Chapter Five: Role of artificial intelligence in cancer diagnostics and therapeutics -- 1. Introduction -- 2. Artificial intelligence in cancer diagnostics -- 2.1. Artificial intelligence in radiographic -- 2.2. Artificial intelligence in digital pathology -- 2.3. Artificial intelligence in endoscopy -- 2.4. Food and Drug administration (FDA) approved artificial intelligence devices with examples -- 3. Artificial intelligence in cancer drug therapy -- 3.1. Artificial intelligence in drug targets -- 3.2. Artificial intelligence in drug discovery -- 3.3. Artificial intelligence in drug repurposing -- 3.4. Artificial intelligence for drug interaction prediction -- 3.5. Artificial intelligence in drug therapy -- 3.6. Artificial intelligence in drug response -- 4. Limitations to artificial intelligence in cancer diagnostics and therapeutics.
• 5. Future prospective of artificial intelligence in cancer management -- References -- Chapter Six: Addressing the diagnosis and therapeutics of malignant tumor cells -- 1. Introduction -- 2. Tumor-related factors -- tumor stage at diagnosis -- 3. Tumor subtype and location -- 4. Prior consultations and usage of health-care services -- 5. Preceding symptomatic presentations -- 6. Health-care factors -- 7. Patient factors -- 8. Age of the patient -- 9. Breast cancer -- 10. Lung cancer -- 11. Prostate cancer -- 12. Ovarian cancer -- 13. Other cancers -- 14. Biomarkers -- imaging technique -- 15. Nanomedicine -- 16. Extracellular vesicles (EV) for cancer diagnosis and therapy -- 17. Natural antioxidants in cancer therapy -- 18. Targeted therapy and immunotherapy -- 19. Gene therapy for cancer treatment -- 20. Conclusion -- Acknowledgment -- References -- Chapter Seven: Insights into genetic predisposition of somatic cancers -- 1. Introduction -- 2. Germline cancers -- 3. Somatic cancers -- 4. Identifying somatic mutations -- 5. Next-generation sequencing (NGS) in mutation detection -- References -- Chapter Eight: The use of tumor markers in prognosis of cancer and strategies to prevent cancer predisposition and progress -- 1. Introduction -- 2. The use of tumor markers in prognosis of cancer -- 2.1. Tumor markers in prognosis -- Prognostic biomarkers in colorectal cancer -- Prognostic biomarkers in hepatocellular carcinoma (HCC) -- Prognostic biomarkers in gastric cancer (GC) -- Prognostic biomarkers in prostatic cancer -- Prognostic biomarkers in breast cancer -- Prognostic biomarkers in lung cancer -- Prognostic biomarkers in epithelial ovarian cancer -- 3. Strategies to prevent cancer predisposition and progress -- 3.1. Cancer prevention -- Strategies for cancer prevention -- Primary cancer prevention -- Secondary cancer prevention.
• Tertiary cancer prevention -- Precision cancer prevention -- Cancer prevention and antioxidants -- Antioxidants -- Antioxidants defense -- The role of antioxidants in cancer prevention -- The role of vitamin C in cancer prevention -- Breast cancer prevention -- Lung cancer prevention -- Liver cancer prevention -- Colorectal cancer prevention -- Skin cancer prevention -- 4. Conclusions and recommendations -- References -- Further reading -- Chapter Nine: Cytogenetics to multiomics in biology of cancer -- 1. Introduction -- 2. Karyotyping -- 2.1. Classical cytogenetic karyotyping -- Banded karyotyping -- Micronucleus -- 2.2. Molecular karyotyping -- Nucleic acid hybridization -- Fish -- Modified FISH techniques -- Comparative genomic array or microarray -- Single-nucleotide polymorphism (SNP) array -- RFLP -- QF-PCR-RFLP -- Next-generation karyotyping -- What is next-gen sequencing (NGS) -- Generations of NGS -- Applications of NGS -- Types of NGS -- Whole-genome sequencing -- Exome sequencing -- Whole transcriptome sequencing -- Multiomics -- Future scope and limitation of multiomics approach -- Single-cell multiomics -- 3. Recent advances -- 3.1. Multiomics and artificial intelligence -- 3.2. Cancer biomarkers -- 3.3. Multiplexed fluorescence, DNA, RNA, and isotope labeling -- 3.4. InfoGenomeR -- 4. Conclusion -- References -- Chapter Ten: Role of noncoding RNA as biomarkers for cancer -- 1. Introduction -- 2. Micro RNA -- 3. Amplification or deletion of miRNA genes -- 4. Dysregulated epigenetic changes -- 5. Defects in miRNA biogenesis machinery -- 5.1. siRNA -- 5.2. piRNA -- 5.3. SnoRNA -- 6. Long noncoding RNAs -- 7. Regulatory functions of housekeeping ncRNAs -- 8. LncRNA modes of action in the nucleus -- 9. Characteristics and functions of long noncoding RNAs -- 10. ncRNAs in clinical practice -- References -- Further reading.
• Chapter Eleven: Viral miRNAs role as diagnostic, prognostic biomarkers for cancer and infectious diseases -- 1. Introduction -- 2. Prospects of viral microRNA as potential biomarkers in cancer -- 3. Antiapoptotic viral miRNAs -- 4. Viral miRNAs in tumor progression -- 5. Prospects of viral microRNAs as potential biomarkers in infectious diseases -- 6. Viral miRNA detection platforms -- 7. Advantages of viral miRNAs as biomarkers -- 8. Future challenges -- Acknowledgment -- Consent for publication -- Conflict of interest -- References -- Chapter Twelve: Pharmacogenomics and oncology: A therapeutic approach for cancer treatment -- 1. Introduction -- 2. Targeting biomarkers in cancer therapy -- 2.1. Thiopurine methyltransferase (TPMT) -- 2.2. BCR-ABL -- 2.3. UGT1A1 -- 2.4. DPYD and 5-FU -- 2.5. BRAF -- 2.6. Estrogen receptor (ESR) -- 2.7. ERBB2 (HER2) -- 2.8. Anaplastic lymphoma kinase (ALK) -- 2.9. HLA -- 2.10. PIK3CA -- 2.11. Gene signature (T-effector) -- 2.12. CD274 -- 2.13. PML-RARA -- 2.14. ROS1 -- 3. Conclusion -- Conflict of interest -- References -- Chapter Thirteen: Obesity: Emerging risk factor for cancer beyond metabolic syndrome -- 1. Introduction -- 2. Epidemiologic evidences supporting the link between obesity and cancer -- 3. Effect of weight gain and weight loss paradigm in regulating cancer risk -- 4. Pathophysiology of obesity mediated cancer -- 5. Prevention and treatment -- 6. Conclusion -- References -- Chapter Fourteen: Homologous repair deficiency and PARP inhibitors in cancer management -- 1. DNA damage and repair -- 2. Homologous recombination deficiency -- 3. Biomarkers to evaluate HRD status -- 3.1. Germline or somatic BRCA mutation -- 3.2. BRCA LOH percentage -- 3.3. Genomic instability/HRD score -- 3.4. Mutation gene signatures -- 3.5. Functional HRD measurement -- Platinum-sensitivity status -- Rad51 foci.
• 4. PARP inhibitors.
• Description based on print version record.